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Lack of Leukocyte Migration Inhibition by Hepatitis B Antigen
and Normal Nonspecific Immunoreactivity in Asymptomatic Carriers
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The immune response to hepatitis B surface antigen (RBs Ag) was studied in 25
asymptomatic carriers by the leukocyte migration-inhibition (LMI) test in agarose.
In the presence of purified RBs Ag, inhibition was demonstrated in only four of 25
carriers, in contrast to 24 of 28 patients who cleared the antigen after acute infection
with hepatitis B. Tuberculin purified protein derivative (PPD) was also used as
an antigen for the LMI test in these carriers. Inhibition was demonstrated in only
12 of 25 individuals who had positive PPD skin tests, in contrast to all of 14 normal
noncarrier individuals with positive PPD skin tests and none of 12 normal noncarrier
individuals with negative PPD skin tests. A nonspecific immunological investigation
of the asymptomatic carriers gave normal results. The lack of an immune response
to HBs Ag was thought to be responsible for the persistence of the antigen and also for
the absence of symptoms.
About 0.2<;'0 of the blood donors in this part of
Europe are carriers of hepatitis B surface antigen
(HBs Ag). Some of these asymptomatic carriers
have slightly elevated levels of transaminases,
whereas others do not exhibit any biochemical
sign of hepatic cytolysis but have slight histologi-
cal abnormalities of the liver. A third group of
these carriers are normal, both biochemically and
histologically [1-3].
Since HBs Ag is usually associated with acute
hepatitis and disappears at the time of recovery,
it is difficult to explain how the antigen can per-
sist in the third (normal) group of carriers with-
out damaging the liver. The fact that HBs Ag
can persist in two conditions as different as the
healthy carrier state and chronic hepatitis is also
problematical.
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The immune state of symptomatic and asymp-
tomatic carriers has been thought to be respon-
sible for the persistence of the antigen. The non-
specific cellular immune response was found to
be impaired by some authors [4-6] and normal
by others [1, 7, 8]. The specific immune response
to HBs Ag has also been studied in vitro in blood
from a limited number of carriers. No inhibi-
tion of leukocyte migration in the presence of
HBs Ag was found by Yeung Laiwah et al. [9] or
by Dudley et al. [10], and inhibition was found
only infrequently by Vittal et al. [11]. However,
Lee et al. [12] observed inhibition in 10 of 37
HBs Ag-positive blood donors. Irwin et al. found
no migration-inhibition factor (MlF) activity in
five carriers tested by an indirect method [13].
Koszikowski et al. [14] did not find any stimula-
tion of lymphocytes by HBs Ag in 10 carriers, and
also found none in 10 patients who had recov-
ered from hepatitis B infection without produc-
ing detectable levels of antibody.
The leukocyte migration-inhibition (LMI) test
in agarose allowed us to use only very small
amounts of purified HBs Ag. With this technique,
we have shown [15] the constant appearance of
a specific inhibition of leukocyte migration by
HBs Ag after recovery from acute infection with
hepatitis B. This inhibition was observed in al-
most all patients who cleared the antigen, where-
as the antibody became demonstrable by radioim-
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munoassay in only half of the patients. The ab-
sence of migration inhibition during and imme-
diately after the acute phase of the disease was
attributed to nonspecific anergy, since migration
inhibition by purified protein derivative (PPD)
disappeared temporarily at that time [16J.
From these findings it was hypothesized that
specific cell-mediated immunity might be respon-
sible for the clearance of HBsAg. The present
study extends this investigation to asymptomatic
carriers. The results demonstrate the absence of
migration inhibition by HBs Ag in all but four of
25 asymptomatic carriers of HBs Ag.
Materials and Methods
Selection of donors. HBs Ag-positive blood
donors were subjected to careful taking of their
medical history, physical examination, and blood
tests, including levels of aspartate aminotrans-
ferase (SGOT) and alanine aminotransferase
(SGPT), prothrombin, alkaline phosphatase, bi-
lirubin, protein, and electrophoresis. Only those
donors who proved to be normal according to
these criteria and who had no history of hepati-
tis were selected for study. This group was re-
examined in the same manner nine to 12 months
later to establish the persistence of HBs Ag in
the blood and the absence of any symptoms. The
possibility of a donor incubating acute hepatitis
could thus be avoided. No liver biopsy was per-
formed because of the absence of indication in
these asymptomatic donors. Titers of HB. Ag
were measured by counterimmunoelectrophore-
sis. In two carriers, HBs Ag was detectable by
radioimmunoassay only. Twenty-five individuals
(18 males and seven females), aged 21-63, were
finally selected for the study.
Nonspecific immune state. The three main
immunoglobulins were measured by radial im-
munodiffusion (Tripartigen Behringwerke, Mar-
burg, Germany). Humoral response was tested
by titration of isoagglutinin, antistreptolysin
(Streptolysin Isti tuto Sierterapico Milanese, Mil-
an, Italy), and antistaphylolysin (Staphylolysin
Behringwerke, Marburg, Germany). Delayed-type
skin reactivity was investigated by skin-testing
with a standard group of five antigens: tuber-
culin PPD (5 units; Statens Seruminstitut, Co-
penhagen, Denmark), streptokinase-streptodorn-
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ase (250 units /ml: Varidase; Lederle, Pearl Riv-
er, N.Y.), candidine (Bencard; Beecham, Brent-
ford, Middlesex, England), trichophytine (Beech-
am), and mumps skin-test antigen (Eli Lilly and
Company, Indianapolis, Ind.).
Purification of HB s Ag. Sera with a titer of
HBs Ag of >1:256 by counterimmunoelectropho-
resis were pooled. HBs Ag was precipitated by
polyethylene glycol 6,000; the precipitate was re-
dissolved in distilled water, dialyzed against 0.05
M sodium barbital buffer (pH 8.6), and further
purified by agarose-block electrophoresis in the
same buffer. The HBs Ag-rich fractions were
pooled and concentrated by vacuum dialysis
against phosphate buffer. The HBs Ag was then
separated from trace amounts of contaminating
proteins by ultracentrifugation on a 10%-30%
(wt/wt) sucrose gradient. The preparation was
sterilized by filtration through Millex microfil-
tel'S (pore size, 45 psn; Millipore Corp., Bedford,
Mass.) and finally was concentrated by vacuum
dialysis (membrane filter SM 132000; Sartorius,
Gottingen, Germany) against medium TC 199
(Difco, Detroit, Mich.), until a titer of 1:16 by
counterimmunoelectrophoresis was reached. No
precipitation line was found in agar double-diffu-
sion with antisera to whole human serum. The
HBs Ag preparation was used undiluted in the
Ll\H test.
LMI test. This test was performed under aga-
rose according to the method of Clausen [17]. De-
tails of this method as performed with HBs
Ag in our laboratory have been described [18].
In brief, 2.5 X 107 leukocytes, containing at least
75% polymorphonuclear leukocytes, were sus-
pended in 0.1 ml of the antigen preparation. The
suspension was incubated for 30 min at 37 C in
an atmosphere of 2.5% CO 2, and 5 fJ-l were in-
troduced into each of eight wells punched in an
agarose layer. After incubation for 18 hr, the
areas of migration were measured by planimetry.
The mean surface area of the eight wells was ex-
pressed as the percentage of the migration in a
control preparation without antigen. Values of
<90% were considered to indicate inhibition.
Leukocytes from each individual were tested in
the presence of two antigens, purified HBs Ag
and tuberculin PPD (25 fJ-g/ml), without pre-
servative. The statistical evaluation was made ac-
cording to Student's t-test for unpaired values.
Leukocyte Migration in HB 8 Ag Carriers
Results
The titers of circulating HB s Ag ranged from 1:
1,024 to 1:1 by counterimmunoe1ectrophoresis,
and, in two cases, antigen was detectable only by
radioimmunoassay (Ausria II; Abbott Laborator-
ies, North Chicago, Ill.). The titer was strikingly
stable during the observation period and never
varied by more than one dilution step. Tests of
hepatic function were normal in all of the in-
dividuals selected for study. On retesting a few
months later, the antigen was still present and
the results of hepatic function tests were normal.
The mean area of leukocyte migration in the
presence of HBs Ag was 101.9<;'0 of that in the
control without antigen (SE ± 3.2). Thus, no im-
mune response to HBs Ag could be demonstrated
in these carriers. Only in cases no. 1, 5, 16, and
23 were individual values of <90% demonstra-
ble.
Figure 1 clearly shows the lack of leukocyte
inhibition by HBs Ag in asymptomatic carriers,
compared with individuals who cleared the an-
tigen after acute infection with hepatitis B. The
difference is significant (t =5.35; P < 0.001).
Leukocytes from carriers did not behave differ-
ently from those from normal individuals (t =
0.34; 0.3 < P < 0.4) or from those from patients
with acute hepatitis B infection (t = 0.32; 0.3 <
P < 0.4) in the presence of HBs Ag.
Inhibition of leukocyte migration in the pres-
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ence of PPD (figure 2) was demonstrable in 12
carriers only, although all 25 carriers had a posi-
tive skin test with PPD. In normal individuals,
however, the LMI test in agarose gave a good cor-
relation with the PPD skin-tests, as shown in fig-
ure 2. The mean area of migration in the pres-
ence of PPD was 71.0% (SE ± 2.3) in PPD-posi-
tive normal individuals, 95.7% (SE ± 4.4) in
PPD-positive patients with acute hepatitis B in-
fection, and 91.8% (SE ± 3.2) in PPD-positive
carriers. Thus, the leukocytes from these asymp-
tomatic carriers behaved, in the presence of
PPD, not like those from normal individuals (t =
4.55; P < 0.001), but in the same manner as
those from acutely infected patients (t = 0.73;
0.2 < P < 0.25). The reproducibility of the LMI
test under agarose was satisfactory, as judged by
the eight simultaneous measurements in each
case; in the four cases with inhibition, all eight
values were <90%. The stimulation observed in a
few cases may be without significance or may be
interpreted as a weak sensitization [18].
Results of nonspecific immunological screen-
ing were normal. Values obtained for the humor-
al parameters were normal, except for a few iso-
lated titers of antibody. This exception can also
occur in normal individuals. Only one case had
low values for all three antibodies tested (two
dilution steps below the lowest limit) and for
IgG (550 mg/100 ml). The delayed hypersen-
sitivity, as judged by the skin tests, was normal
in all patients.
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Figure 1. Migration, in the presence
of purified hepatitis B surface anti-
gen (RB s Ag), of leukocytes from
normal individuals (left), patients
during and after acute hepatitis B
infection (center), and asympto-
matic carriers of RBs Ag (right).
Points represent the surface of mi-
gration expressed as the percentage
of the migration in a control pre-
paration without antigen. The short
horizontal lines are means ± SD.
Broken line represents 100% migra-
tion.
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Figure 2. Migration, in the presence
of purified protein derivative (PPD),
of leukocytes from normal PPD-
negative individuals and normal
PPD-positive individuals (left), PPD-
positive individuals during acute
hepatitis B infection (center), and
PPD-positive asymptomatic carriers
of hepatitis B surface antigen (right).
The short horizontal lines are means
± SD. Broken line represents 100%
migration.
PPD
skin test neg. pes. pes. pes.
Discussion
The inhibition of leukocyte migration by HBs
Ag in carriers occurred infrequently (four of 25
carriers). This finding contrasts with the nearly
constant inhibition we observed in patients who
cleared HBs Ag (24 of 28 patients). Consequent-
ly, we believe that the specific immune response
demonstrated by the LMI test is probably respon-
sible for elimination of the antigen, which oc-
curs during recovery from hepatitis B infection,
and that the lack of this response may explain
the carrier state.
Nearly all authors consider the LMI test as
an index of cell-mediated immunity. Although
this hypothesis has not been proven, the follow-
ing findings encourage us to support it for the
moment. In our experiments with HBs Ag as an
antigen, migration inhibition did not correlate
with antibody production [15, 18]. In our experi-
ments with PPD, the correlation with the results
of delayed skin tests was excellent (figure 2).
Furthermore, Lambert et al.' and Trepo et al. [19]
found no relation between the presence of HBs
Ag-anti-Hfs, Ag complexes and any of the condi-
tions studied here.
1 P. H. Lambert, E. Tribollet, A. Celada, K. Madalinski
P. C. Frei, P. A. Miescher, "Circulating Immune Complexe~
I~~ol~ingHBsAg in Patients with Acute and Chronic Hepa-
tItIS III Healthy Carriers and in Polyarteritis Nodosa,"
manuscript in preparation.
. Our observations also contribute to explana-
nons of the absence of lesions in the carriers.
The lesions of hepatitis cannot, of course, be
produced by the virus itself. They might be the
consequence of the immune response demon-
strated by the LMI test, and the lack of this re-
sponse in carriers would explain the absence of
cytolysis in the liver. One must then consider the
reason that this response could not be demon-
strated during the acute phase of hepatitis (fig-
ure 1), when the liver is most severely attacked.
This lack of response is probably related to a
broad, nonspecific anergy during the acute phase.
We have shown [16, 18] that the migration of
leukocytes from PPD-positive individuals was not
inhibited by PPD during hepatitis. Experiments
with PPD as antigen (figure 2).also showed that
leukocytes from some carriers behaved like those
from patients with acute hepatitis B infection;
the mean surface areas of migration were 91.8%
and 95.7%, respectively, without significant dif-
ference between the two values. The anergy dem-
onstrable in vitro during the acute disease exists,
to a lesser extent, in healthy carriers. Thus, it
seems that the circulating agent can itself pro-
duce a nonspecific anergy, even in the absence
of tissue damage. Note that the anergy in these
two conditions was not demonstrable by the skin
tests. These tests may be more sensitive than the
LMI test or may show a slightly different type of
response.
Leukocyte Migration in HB s Ag Carriers
The impairment of the immune response dem-
onstrable by the LMI test in carriers seems to
be an isolated defect, since the results of the non-
specific immunological investigation were indis-
tinguishable from those one would obtain in nor-
mal individuals. Only one carrier had low titers
of antibody and a low IgG level. In this respect,
our results differ from those of others [4-6]. This
difference is probably related to our stricter cri-
teria of selection, which excluded individuals
with biological signs of hepatic disease.
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